Samsung BioLogics IPO may raise US$2bil

  • Business Premium
  • Wednesday, 05 Oct 2016

SEOUL: Samsung BioLogics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said its initial public offering is expected to raise as much as US$2bil in what is set to be South Korea's third-largest IPO.

The listing is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Next In Business News

CPO futures likely to undergo technical correction next week Premium
Econpile issues termination notice to Gabungan Strategik Premium
Intel's US$20bil Ohio factory could become world's largest chip plant Premium
Shrunken US oil inventories point to chronic under-supply Premium
Royal Dutch no more - Shell officially changes name Premium
Oil price slides, but climbs for 5th week on supply concerns Premium
GLOBAL MARKETS-Bond yields tumble as Netflix fuels stock market sell-off Premium
Rising interest rate fallout unlikely Premium
Policy normalisation can lend support to ringgit Premium
Short Position - Green bond, O&G funding, Going the EV way Premium

Others Also Read